Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

Background Glucagon-like peptide-1 (GLP-1) analogues reduce hepatic steatosis, concentrations of liver enzymes, and insulin resistance in murine models of fatty liver disease. These analogues are licensed for type 2 diabetes, but their efficacy in patients with non-alcoholic steatohepatitis is un...

Full description

Bibliographic Details
Main Authors: Armstrong, Matthew James, Gaunt, Piers, Aithal, Guruprasad P., Barton, Darren, Hull, Diana, Parker, Richard, Hazlehurst, Jonathan M., Guo, Kathy, Abouda, George, Aldersley, Mark A., Stocken, Deborah, Gough, Stephen C., Tomlinson, Jeremy W., Brown, Rachel M., Hübscher, Stefan G., Newsome, Philip N.
Format: Article
Published: Elsevier 2015
Online Access:https://eprints.nottingham.ac.uk/39309/

Internet

https://eprints.nottingham.ac.uk/39309/

Similar Items